| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
The purpose of this study is to evaluate the feasibility of combination therapy of RFA and intratumoral cisplatin injection to lung tumor. VX2 tumor colonized rabbit models were prepared, and RFA and intratumoral cisplatin injection was performed. Rabbits modeles were randomly assigned to 4 groups of control group (untreated group), RFA alone group, intratumoral cisplatin injection group, RFA + ciplatin injection group. Survivals were evaluated by by the Kaplan-Meier method. The median survival time of the control group, RFA alone group, intratumoral cisplatin injection group, RFA + intratumoral cisplatin injection group were (24.5 / 40.0 / 31.0 / 80.0 days), respectively. The survival rates on the 20th, 40th, 60th, and 80th days were (62.5%, 0%, 0%, 0% / 100%, 50%, 25%, 25% / 62.5%, 25%, 12.5% , 12.5% / 100%, 100%, 75%, 62.5%). The survival time of the combination therapy group was significantly longer than the other 3 groups.
|
